NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
This article was originally published in The Tan Sheet
Executive Summary
A two-day joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is scheduled for Jan. 13-14, 2005
You may also be interested in...
Mevacor OTC Actual-Use Study Data May Answer Future NDAC Questions
Nearly half of high-risk patients in the Mevacor OTC actual-use study took the low-dose statin only after securing approval from a doctor, writes Eric Brass, MD/PhD, UCLA Medical Center, in a supplement to the Nov. 15 American Journal of Cardiology
“Pharmacy Care” OTC Category Considered By APhA Task Force
A new category of "pharmacy care" drugs could broaden access to certain over-the-counter drugs, according to the American Pharmacists Association
J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group
J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD